Abstracts tagged "Comorbidity"

Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 2079 • ACR Convergence 2025
Association Between Symptomatic Knee Osteoarthritis and Health-Related Quality of Life in Individuals with Type 2 Diabetes: A Cross-Sectional Study
Abdalmohsen Almodahka¹, Alanna Weisman², Baiju Shah³, Tristan Watson⁴, Ian stanaitis⁵, Amish Parikh⁶, Robert Goldberg⁶, Lorraine Lipscombe⁷, Gillian Hawker¹ and Lauren King¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network Toronto General Hospital Site/Sinai Health System, Toronto, ON, Canada, ³Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁴Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁵Research and Innovation Institute, Women’s College Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Division of Endocrinology, Department of Medicine, Trillium Health Partners, Mississauga, ON, Canada, Toronto, ON, Canada, ⁷Department of Medicine, University of Toronto, Research and Innovation Institute, Women’s College Hospital, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (OA) and type 2 diabetes (T2D) commonly coexist, but their combined impact on health-related quality of life (HRQoL) remains understudied. Our objective…
Abstract Number: 0215 • ACR Convergence 2025
Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
Alexandra Kobza¹, Camille Bourgeois², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹University of Calgary, North Vancouver, BC, Canada, ²Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), face elevated risk for comorbidities that complicate disease management. Although rheumatology societies…
Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 2128 • ACR Convergence 2025
Prevalence of Risks and Complications in a Longitudinal International Cohort of Children with Chronic Nonbacterial Osteomyelitis (CNO)
Jessica Kent¹, Eveline Wu², Melissa Oliver³, Sivia Lapidus⁴, Ummusen Akca⁵, Adriel Liau⁶, Pratyush Kore⁷, Ian Muse⁸, Ava Klein⁶, Emily Deng⁶, Iris Hamilton⁶, Haodong Chen⁷, Megan Nguyen⁷, Tianai Li⁹, Avril Wilson⁷, Jasmine Morden⁷, Shima Yasin¹⁰, Aleksander Lenert¹¹, Sara M. Stern¹², Antonella Insalaco¹³, Manuela Pardeo¹⁴, Gabriele Simonini¹⁵, Edoardo Marrani¹⁶, Xing Wang⁶, Bin Huang¹⁷, Leonard Kovallick¹⁸, Natalie Rosenwasser¹⁹, Erin Balay-Dustrude²⁰, Doaa Mosa²¹, Katerina Bouchalova²², Andrea Cabova²³, Jenna Thomason²⁰, Lori Tucker²⁴, Hermann Girschick²⁵, Ronald laxer²⁶, Marinka Twilt²⁷, Georgina Tiller²⁸, Jonathan Akikusa²⁹, Christian Hedrich³⁰, Karen Onel³¹, Fatma Dedeoglu³², Seza Özen³³, Polly Ferguson³⁴ and Yongdong (Dan) Zhao³⁵, ¹Medical College of Wisconsin, Wauwatosa, WI, ²UNC Chapel Hill, Chapel Hill, NC, ³Indiana University, Indianapolis, IN, ⁴Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, ⁵Hacettepe University, Ankara, Turkey, ⁶Seattle Children's Hospital, Seattle, ⁷Seattle Children’s Research Institute, Seattle, ⁸University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, ⁹Seattle Children's Research institute, Seattle, ¹⁰Univeristy of Iowa, Iowa City, ¹¹University of Iowa, Iowa City, IA, ¹²University of Utah, Salt Lake City, UT, ¹³IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ¹⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹⁵Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ¹⁶University of Florence, Firenze, Italy, ¹⁷Cincinnati Children's Hospital, Cinciannati, OH, ¹⁸The University of North Carolina at Chapel Hil, Chapel Hill, ¹⁹Seattle Children's Hospital, seattle, WA, ²⁰University of Washington, Seattle, WA, ²¹Mansoura University Hospitals, Mansoura City, Egypt, ²²Palacký University Olomouc, Olomouc, Czech Republic, ²³Faculty of Medicine and Dentistry Palacky University Olomouc, Olomouc, Czech Republic, ²⁴BC Children's Hospital, Vancouver, BC, Canada, ²⁵Vivantes Clinic Friedrichshain, Wuerzburg, Germany, ²⁶The Hospital for Sick Children, Toronto, ON, Canada, ²⁷Alberta Children's Hospital, Alberta, Canada, ²⁸Royal Children’s Hospital, Melborne, Australia, ²⁹The Royal Children's Hospital, Parkville, Victoria, Australia, ³⁰University of Liverpool, Liverpool, United Kingdom, ³¹HSS, New York, NY, ³²Boston Children's Hospital, Boston, MA, ³³Hacettepe University Medical Faculty, Ankara, Turkey, ³⁴University of Iowa Carver College of Medicine, Iowa City, IA, ³⁵Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is associated with various comorbidities and long-term complications. The CHronic nonbacterial Osteomyelitis International Registry (CHOIR) is a multi-national database that…
Abstract Number: 0436 • ACR Convergence 2025
Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
Andrea Mazariego and Maria Greenwald, Desert Medical Advances, Rancho Mirage, CA
Background/Purpose: Patients with rheumatic disease have an increased risk for thrombotic events and major adverse cardiac events (MACE) due to systemic inflammation. Bleeding time is…
Abstract Number: 1413 • ACR Convergence 2025
Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
Esther Toledano¹, Carlos Villegas², Carolina Cristina Chacón³, Cristina Hidalgo Calleja³, Belén Miguel³, Laura Blanco³, Ana Turrión⁴, Olga Compán⁵, Manuel Martín⁴, Susana Gómez³ and Carlos Montilla³, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Faculty of Medicine, University of Salamanca, Salamanca, Spain, ³Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Spain, ⁵Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain
Background/Purpose: Restless legs syndrome (RLS) is a chronic neurological disorder associated with brain iron metabolism. Although RLS has been linked to various immune-mediated inflammatory diseases,…
Abstract Number: 2232 • ACR Convergence 2025
Risk factors for hospitalizations in a large, contemporary rheumatoid arthritis patient cohort
Argyro Lazarini¹, Konstantinos Thomas², EVRIPIDIS KALTSONOUDIS³, Paraskevi V Voulgari⁴, Alexandros Drosos⁵, Argyro Repa⁶, Ainour Molla ismail Sali⁶, Prodromos Sidiropoulos⁶, Kalliopi Fragkiadaki¹, Maria Tektonidou⁷, Petros Sfikakis⁸, Panagiota Tsatsani⁹, Sousana Gazi⁹, Evangelia Argyriou¹⁰, Kyriaki Boki¹⁰, Pelagia Katsimpri¹, Dimitrios Boumpas¹, Gerasimos Evangelatos¹¹, Alexios Iliopoulos¹², Konstantina Karagianni¹³, Lazaros Sakkas¹³, Konstantinos Melissaropoulos¹⁴, Panagiotis Georgiou¹⁴, Eleftheria Grika¹, PANAYIOTIS VLACHOYIANNOPOULOS¹, Theodoros Dimitroulas¹⁵, Alexandros Garyfallos¹⁶, Konstantinos Georganas¹⁷, Periklis Vounotrypidis¹⁸, Konstantinos Ntellis¹⁹, Georgios Kitas²⁰ and Dimitrios Vassilopoulos²¹, ¹Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ³Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ⁴Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ⁵Rheumatology Clinic, University of Ioannina, Ioannina, Greece, ⁶Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ⁷National and Kapodistrian University of Athens, Athens, Greece, ⁸NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁹Rheumatology Unit, KAT Hospital, Athens, Greece, ¹⁰Rheumatology Unit, Sismanoglio Hospital, Athens, Greece, ¹¹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹²⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ¹³Department of Rheumatology, University of Thessaly, Larissa, Greece, ¹⁴Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, ¹⁵Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ¹⁶⁴th Department of Medicine, Aristotle University, Thessaloniki, Greece, ¹⁷Private office, Athens, ¹⁸Private office, Thessaloniki, Greece, ¹⁹Private office, Kalamata, Greece, ²⁰Hygeia Hospital, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece
Background/Purpose: There are limited data regarding the recent trends and risk factors for hospitalization in patients with rheumatoid arthritis (RA). Our aim was to estimate…
Abstract Number: 0438 • ACR Convergence 2025
Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis
Bindee Kuriya¹, Susan J. Bartlett², Marie-France Valois³, Janet Pope⁴, Carter Thorne⁵, Carol Hitchon⁶, Hugues Allard-Chamard⁷, Glen Hazlewood⁸, Gilles Boire⁹, Louis Bessette¹⁰ and Vivian Bykerk¹¹, ¹Mount Sinai Health, Toronto, Canada, ²McGill University, Beaconsfield, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Centre of Arthritis Excellence, Newmarket, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Retired, Sherbrooke, QC, Canada, ¹⁰Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiorenal-metabolic (CRM) therapies, such as SGLT-2 inhibitors and GLP-1 agonists, are medications that target interconnected pathways between cardiovascular, renal, and metabolic systems and may…
Abstract Number: 1421 • ACR Convergence 2025
Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
Lily Mikolajczak¹, Helena Kuhn¹, Leslie Harrold² and George Reed³, ¹Kuchnir Dermatology and Dermatologic Surgery, Milford, MA, ²CorEvitas, Northborough, MA, ³University of Massachusetts Chan Medical School, Worcester, MA
Background/Purpose: Patients with psoriatic arthritis often report having brain fog, describing symptoms such as forgetfulness, difficulty thinking and memory issues. It has been hypothesized that…
Abstract Number: 2249 • ACR Convergence 2025
Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies
Marina Pavía-Pascual¹, Marina Sánchez-Lucas², Camille Bourgeois³, Maria Teresa Schiaffino Garcia-Villanova⁴, Julia Martínez Barrio⁵, Juan Molina-Collada⁶, Esther Chamorro De Vega⁷, José María álvaro-Gracia álvaro⁸ and Isabel Castrejón Fernández⁹, ¹Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ²Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain, ³Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ⁴Department of Immunology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ⁶Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ⁷Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁸Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Department of Medicine, Complutense University, Madrid, Spain., Madrid, Madrid, Spain, ⁹MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the second leading cause of mortality in rheumatoid arthritis (RA) but often goes underdiagnosed due to its variable clinical…
Abstract Number: 0459 • ACR Convergence 2025
Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Rinko Katsuda¹, Akiko Kitagawa¹, Masayuki Azukizawa², Musuzu Fujimori¹ and Tetsuji Kawamura³, ¹Department of Rheumatology, NHO Himeji Medical Center, Japan, Himeji, Japan, ²Department of Orthopaedic Surgery, NHO Himeji Medical Center, Japan, Himeji, Japan, ³Department of Respiratory Medicine, NHO Himeji Medical Center, Japan, Himeji, Japan
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common and serious extra-articular manifestation of RA, contributing to ~10% of RA-related mortality. Acute exacerbation (AE)…
Abstract Number: 1452 • ACR Convergence 2025
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Nikolaos Kougkas¹, Konstantinos Tsafis², Dimitrios Deligeorgakis³, Vasileios Papadopoulos⁴, Nikolaos Fytanidis⁵, Michail Krikelis⁶, Evangelia Mole⁷, Sousana Gazi⁷, Nikolaos Koletsos⁸, EVRIPIDIS KALTSONOUDIS⁹, Paraskevi V Voulgari¹⁰, Anastasios Karamanakos¹¹, Maria Pappa¹², Maria Tektonidou¹³, Petros Sfikakis¹⁴, Kalliopi Klavdianou¹⁵, aggelos Banos¹⁶, Eleni Kalavri¹⁷, Konstantinos Kottas¹⁸, Gkikas Katsifis¹⁸, MARIA KONSTA¹⁹, Eleftheria Grika²⁰, Charalampos Sfontouris²⁰, Evgenia Mavrea²¹, Christos Koutsianas²², Evangelia Kataxaki²³, Eleni Sampatakaki²⁴, Konstantina Zoupidou²⁵, Pelagia Katsimpri²⁶, Alexios Iliopoulos²⁷, Georgios Iliopoulos²⁸, Dimitrios Daousis²⁹, Ilias Bournazos³⁰, DIMITRIOS KAROKIS³¹, Dimos Patrikos³², Theodoros Dimitroulas³, Dimitrios Vassilopoulos²¹, George E Fragoulis³³ and Charalampos Papagoras³⁴, ¹⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ²Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Thessaloniki, Greece, ³Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ⁴Department of Medicine Democritus University of Thrace, Laboratory of Anatomy, Alexandroupolis, Greece, Alexandroupolis, Evros, Greece, ⁵University Hospital of Alexandroupolis, Democritus University of Thrace, First Department of Internal Medicine, Alexandroupolis, Greece, Alexandroupolis, Greece, ⁶KAT Hospital, Athens, Department of Rheumatology, Athens, Greece,, Athens, Attiki, Greece, ⁷Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁸School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ¹¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Laiko”, First Department of Propedeutic and Internal Medicine, Athens, Greece, Athens, Greece, ¹²Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ¹³National and Kapodistrian University of Athens, Athens, Greece, ¹⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ¹⁵Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Kaisariani Athens, Greece, ¹⁶Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Attiki, Greece, ¹⁷"Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Greece, ¹⁸Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, Athens, Greece, ¹⁹Sismanoglion Hospital, Athens, Greece, Marousi, Attiki, Greece, ²⁰Evaggelismos Athens General Hospital, Department of Rheumatology, Athens, Greece, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece, ²²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece, ²³General Hospital Elefsinas Thriaseio,Attica, Rheumatology Department, Athens, Greece, Athens, Greece, ²⁴Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ²⁵Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Greece, ²⁶Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²⁷⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ²⁸Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patras, Akhaia, Greece, ²⁹Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patra, Greece, ³⁰Private practice, Athens, Greece, Athens, Greece, ³¹Private practice, Patras, Greece, Patras, Greece, ³²Private practice, Athens, Greece, Ag. Paraskevi, Greece, ³³First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ³⁴First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that significantly impairs quality of life. Although biologic and targeted synthetic DMARDs (b/tsDMARDs) have improved disease…
Abstract Number: 2251 • ACR Convergence 2025
Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexandra Schmidt², Alexander Peterson², Aliyah Pabani³, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁴, Noel Weiss¹ and Namrata Singh⁵, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³Johns Hopkins, Washington, DC, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of malignancies, particularly lung cancer, relative to the general population1. However, the association between RA…
Abstract Number: 0476 • ACR Convergence 2025
Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence
Maxim Korolev¹, Alexander Dubikov², Daria Bukhanova³, Alina Egorova³, Eugenyi Alekseev⁴, Sofia Kuzkina⁵ and Mikhail Samsonov³, ¹Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia, ²Rheumatology clinic of Professor Dubikov A.I., Vladivostok, Russia, ³R-Pharm JSC, Moscow, Russia, ⁴"R-Pharm", JSC, Moscow, Russia, ⁵R-Pharm, Moscow, Russia
Background/Purpose: Comorbidities may affect the efficacy of bDMARDs in rheumatoid arthritis (RA). Post-hoc analysis of the randomized clinical trial (RCT) data shows that the efficacy…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].